Metastatic Cancer in America 2026
Metastatic cancer — the stage at which cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system to form new tumors in distant organs — remains one of the most serious and complex medical challenges facing the United States today. When a cancer is described as metastatic, it means the disease has moved beyond its point of origin, whether that is the breast, lung, colon, prostate, or another site, and has taken hold in areas such as the liver, lungs, bones, or brain. In 2026, this advanced form of cancer continues to account for a disproportionate share of cancer deaths in the country, even as science and medicine advance at a rapid pace. The American Cancer Society, drawing on data compiled by the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC), projects 2,114,850 new cancer cases in the United States this year alone — and a significant portion of those will involve patients who are already at, or who will progress to, the distant-stage (metastatic) category.
What makes metastatic cancer especially important to understand in 2026 is the shifting landscape of both diagnosis and survival. For decades, a metastatic diagnosis carried a near-certain prognosis of rapid decline. Today, that story is changing — but slowly, and unevenly. The 5-year relative survival rate for distant-stage (metastatic) cancer in the US has climbed to 35% for diagnoses made during 2015–2021, up from just 17% in the mid-1990s. That progress is real, meaningful, and hard-won. Yet it also exposes a stark gap: the overall 5-year survival rate for all cancers combined now sits at a milestone 70%, meaning metastatic patients are still surviving at roughly half the rate of the broader cancer population. Understanding the data behind these numbers — who gets metastatic cancer, which types carry the worst prognoses, how survival differs by race and income, and what the latest government-sourced statistics tell us — is the first step toward informed advocacy, better health decisions, and targeted policy action.
Interesting Key Facts: Metastatic Cancer in the US 2026
| Fact | Data Point |
|---|---|
| Overall 5-year survival rate — all cancers (2015–2021) | 70% |
| 5-year survival rate — distant-stage (metastatic) cancer | 35% |
| Metastatic survival rate in the mid-1990s (distant-stage) | 17% |
| Projected total new cancer cases in the US, 2026 | 2,114,850 |
| Projected total cancer deaths in the US, 2026 | 626,140 |
| Cancer deaths per day in the US, 2026 | ~1,720 |
| New cancer diagnoses per day in the US, 2026 | ~5,800 |
| Cancer deaths averted in the US since 1991 (through 2023) | 4.8 million |
| People living with a history of cancer in the US (as of Jan 1, 2025) | 18.6 million |
| People living with metastatic breast, prostate, lung, colorectal, bladder cancer or metastatic melanoma (2018 est., NCI) | 623,405 |
| Estimated increase in metastatic cancer survivors by 2025 (NCI) | Over 693,400 |
| Estimated metastatic breast cancer survivors in the US | ~168,000 |
| Metastatic lung cancer 5-year survival — mid-1990s vs. 2015–2021 | 2% → 10% |
| Metastatic melanoma 5-year survival — mid-1990s vs. 2015–2021 | 16% → 35% |
| Metastatic rectal cancer 5-year survival — mid-1990s vs. 2015–2021 | 8% → 18% |
| Myeloma 5-year survival — mid-1990s vs. 2015–2021 | 32% → 62% |
| Liver cancer 5-year survival — mid-1990s vs. 2015–2021 | 7% → 22% |
| Distant-stage pancreatic cancer 5-year survival rate | 3% |
| Distant-stage breast cancer (metastatic) 5-year survival rate | 33% |
| Distant-stage prostate cancer 5-year survival rate | 37% |
| Non-Hispanic Black men — burden of Stage IV cancer diagnosis (per 100,000) | 337 per 100,000 |
| Non-Hispanic Asian/Pacific Islander women — Stage IV cancer rate (per 100,000) | 117 per 100,000 |
| Lifetime probability of being diagnosed with invasive cancer (men) | 39.2% |
| Lifetime probability of being diagnosed with invasive cancer (women) | 38.7% |
| Cancer deaths in 2026 attributable to smoking | 182,830 |
Sources: American Cancer Society Cancer Facts & Figures 2026; NCI SEER Program; CDC National Program of Cancer Registries; NCI Division of Cancer Control and Population Sciences (DCCPS); Siegel RL et al., CA Cancer J Clin. 2026. doi:10.3322/caac.70043
The numbers above tell a story of genuine progress shadowed by persistent inequity. The 5-year relative survival rate for metastatic (distant-stage) cancer has more than doubled — from 17% in the mid-1990s to 35% today — a transformation driven largely by immunotherapies, targeted molecular drugs, and improved screening. That headline statistic is important: it means that for every 100 Americans diagnosed with metastatic cancer today, 35 are expected to be alive five years later, compared to just 17 a generation ago. That doubling, as the American Cancer Society’s chief scientific officer William Dahut noted in January 2026, is “really driven by new therapies” — not just earlier detection. At the same time, the data reveals the severity of the challenge still ahead. With 626,140 projected cancer deaths in 2026 — roughly 1,720 every single day — the absolute burden remains staggering. The fact that 2,114,850 new cases are expected this year underscores that even as survival improves, the pipeline of patients entering treatment at advanced stages remains very large. For metastatic-specific patients, the figures on site-specific survival (from 3% for distant-stage pancreatic cancer to 33% for metastatic breast cancer to 37% for distant-stage prostate cancer) highlight that outcomes vary enormously by cancer type — and that some forms of the disease remain far more lethal than others even in 2026.
Overall Cancer Burden and Metastatic Context in the US 2026
| Metric | Data |
|---|---|
| Total projected new cancer cases, US 2026 | 2,114,850 |
| Total projected cancer deaths, US 2026 | 626,140 |
| Men diagnosed with cancer in 2026 | 1,094,070 |
| Women diagnosed with cancer in 2026 | 1,020,780 |
| Men who will die from cancer in 2026 | 327,290 |
| Women who will die from cancer in 2026 | 298,000 |
| % of diagnoses in individuals aged 65 and older | 60% |
| % of diagnoses in individuals younger than 50 | 12% |
| % of diagnoses in individuals aged 50–64 | 28% |
| 5-year relative survival — all cancers combined (2015–2021) | 70% |
| 5-year relative survival — regional-stage disease (2015–2021) | 69% |
| 5-year relative survival — distant-stage/metastatic disease (2015–2021) | 35% |
| Regional-stage survival in mid-1990s | 54% |
| Distant-stage survival in mid-1990s | 17% |
| Cancer deaths averted since 1991 (through 2023) | 4.8 million |
| Cancer mortality rate change since 1991 | Declined 34% |
Source: Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. doi:10.3322/caac.70043. Data compiled from NCI SEER Program and CDC National Center for Health Statistics.
The sheer scale of the 2026 cancer burden in the United States is something that demands direct confrontation. When 2,114,850 Americans are projected to receive a new cancer diagnosis in a single year, it is worth remembering that a portion of those diagnoses will be confirmed at a metastatic or distant stage from day one — and many more patients diagnosed at earlier stages will eventually progress. The 5-year relative survival rate gap between regional-stage disease (69%) and distant-stage disease (35%) makes one thing unmistakably clear: the stage at which cancer is caught remains one of the single most powerful determinants of whether a patient survives. This is precisely why the overall cancer mortality rate declining by 34% since 1991 — averting an estimated 4.8 million deaths — is a public health achievement directly tied to better screening, earlier detection, and treatment innovation. Yet 626,140 projected deaths in 2026 — more than 1,700 every day — remains a brutal reminder that progress, while real, is not yet sufficient for patients whose cancer is found late.
5-Year Survival Rates for Metastatic (Distant-Stage) Cancers in the US 2026
| Cancer Type | 5-Year Survival — Mid-1990s | 5-Year Survival — 2015–2021 | Change |
|---|---|---|---|
| All cancers — distant stage | 17% | 35% | +18 pts |
| Lung cancer — distant/metastatic | 2% | 10% | +8 pts |
| Melanoma — distant/metastatic | 16% | 35% | +19 pts |
| Rectal cancer — distant/metastatic | 8% | 18% | +10 pts |
| Myeloma | 32% | 62% | +30 pts |
| Liver cancer | 7% | 22% | +15 pts |
| Breast cancer — distant/metastatic | N/A | 33% | — |
| Prostate cancer — distant stage | N/A | 37% | — |
| Pancreatic cancer — distant/metastatic | ~4% (overall) | 3% (distant stage) | Minimal |
| Pancreatic cancer — all stages combined | 4% | 13% | +9 pts |
| Lung cancer — regional stage | 20% | 37% | +17 pts |
Source: Siegel RL et al. Cancer statistics, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70043. NCI SEER Program data for diagnoses 2015–2021 with vital status follow-up through 2022. Historical comparisons based on SEER 9 areas (mid-1990s). Pancreatic distant-stage data from NCI SEER Cancer Stat Facts: Pancreatic Cancer and Pancreatic Cancer Action Network citing Cancer Facts & Figures 2026.
The survival data for individual metastatic cancer types reveals one of the most compelling narratives in modern oncology — the story of where immunotherapy and targeted therapy have worked, and where they have not yet delivered. The most dramatic progress belongs to myeloma, where the 5-year survival rate has nearly doubled from 32% to 62%, and to metastatic melanoma, where it has more than doubled from 16% to 35% thanks to breakthrough checkpoint inhibitor drugs. Metastatic lung cancer saw its survival climb from a near-certain death sentence of 2% in the mid-1990s to 10% in 2015–2021 — still low, but representing a fivefold improvement that translates into thousands of additional life-years across the US population annually. The contrast with distant-stage pancreatic cancer — still sitting at just 3% five-year survival — is sobering. Even though pancreatic cancer’s overall survival has improved from 4% to 13% over the last two decades, patients diagnosed at the metastatic stage continue to face one of the most lethal prognoses of any cancer type. The 35% five-year survival rate for metastatic breast cancer and 37% for distant-stage prostate cancer show that hormone-driven cancers, where targeted endocrine therapies and drugs like CDK4/6 inhibitors have transformed care, continue to outperform the broader metastatic cancer average.
Metastatic Cancer Survivors Living in the US 2026
| Metric | Data |
|---|---|
| Total cancer survivors in the US (as of January 1, 2025) | 18.6 million |
| Projected cancer survivors in the US by 2035 | Over 22 million |
| People living with metastatic breast, prostate, lung, colorectal, bladder cancer or metastatic melanoma in the US (2018 est.) | 623,405 |
| Projected increase in those living with metastatic cancer in the US by 2025 (NCI estimate) | Over 693,400 |
| Estimated US survivors living with metastatic breast cancer (Stage 4) | ~168,000 |
| % of cancer survivors diagnosed within the past 10 years | 51% |
| % of cancer survivors aged 60 years and older | 79% |
| Most prevalent cancer among male survivors | Prostate cancer (3,552,460) |
| Most prevalent cancer among female survivors | Breast cancer (4,305,570) |
| Projected increase in survivors living 5+ years post-diagnosis (2022–2040) | ~53% increase to 19.2 million |
Source: NCI Division of Cancer Control and Population Sciences (DCCPS), Statistics and Graphs, cancercontrol.cancer.gov. Data: Gallicchio L et al. J Natl Cancer Inst. 2022;114(11):1476–1483. American Cancer Society Cancer Treatment and Survivorship Statistics, 2025. NCI SEER Program.
Living with metastatic cancer is not simply a medical situation — it is a long-term reality for a growing number of Americans, and the 2026 data makes that clear. As of January 2025, 18.6 million Americans are living with a history of cancer, and that number is on a trajectory to exceed 22 million by 2035. Within that population, a specific subset — those living with active or past metastatic diagnoses — numbers at least 693,400 across the key metastatic cancer types tracked by the NCI, up from 623,405 measured in 2018. The ~168,000 Americans currently living with Stage 4 metastatic breast cancer represent a particularly important cohort: three-quarters of them were originally diagnosed at an earlier stage before their cancer progressed, and many are now in long-term treatment managing the disease as a chronic illness rather than a terminal one. The survivorship picture is aging, too — 79% of all cancer survivors in the US are aged 60 or older, which has deep implications for healthcare systems, Medicare spending, and the kind of support services patients need as they navigate years of ongoing treatment.
Leading Metastatic Cancer Types by Deaths in the US 2026
| Cancer Type | Estimated US Deaths 2026 | Distant-Stage % at Diagnosis |
|---|---|---|
| Lung and bronchus cancer | 124,990 | High (~57% at distant stage) |
| Colorectal cancer | Est. ~53,000 (2nd to lung combined) | ~22% at distant stage |
| Pancreatic cancer | Est. ~51,750 | ~51% diagnosed at distant stage |
| Breast cancer (women) | 42,140 | ~6% first diagnosed at distant stage |
| Prostate cancer | 36,320 | ~8% at distant stage |
| Ovarian cancer | — | 49% diagnosed at distant stage (2018–2022) |
Source: American Cancer Society Cancer Facts & Figures 2026; Siegel RL et al., CA Cancer J Clin. 2026. doi:10.3322/caac.70043; NCI SEER Cancer Stat Facts (seer.cancer.gov); Pancreatic Cancer Action Network citing Cancer Facts & Figures 2026.
The mortality data for leading metastatic cancers in 2026 paints a clear picture of where the greatest unmet need remains. Lung cancer is, by itself, expected to claim 124,990 lives in 2026 — more than the estimated deaths from colorectal and pancreatic cancers combined, which together rank second and third. This dominance in mortality is driven heavily by the fact that lung cancer is so often diagnosed at an advanced or metastatic stage, when treatment options are limited and survival rates — even after the remarkable advances of the past two decades — remain in the single digits to low teens for distant-stage disease. Pancreatic cancer is particularly alarming in its stage distribution: approximately 51% of pancreatic cancer patients are diagnosed at the distant stage, meaning over half of all new cases are already metastatic at the time of first diagnosis, which explains why its overall five-year survival rate of 13% remains among the lowest of all major cancers despite modest recent gains. Ovarian cancer is another cancer where late-stage diagnosis is the norm rather than the exception — 49% of cases are found at a distant stage even in the most recent data period of 2018–2022, down from 57% a decade earlier, reflecting slow but real improvement in detection. Breast cancer, by contrast, has only ~6% of cases first diagnosed at the distant stage, which is a testament to decades of successful mammography and awareness campaigns.
Metastatic Cancer Racial and Ethnic Disparities in the US 2026
| Population Group | Key Disparity / Data Point |
|---|---|
| Non-Hispanic Black men | Highest burden of Stage IV cancer diagnosis: ~337 per 100,000 |
| Non-Hispanic Asian/Pacific Islander women | Lowest Stage IV cancer rate: ~117 per 100,000 |
| Black women | Higher rates of triple-negative and metastatic breast cancer vs. all other groups |
| Black patients — metastatic breast cancer systemic therapy receipt | 59% (vs. 68% White, per SEER-Medicare data 2016–2020) |
| Black patients — metastatic colorectal cancer systemic therapy receipt | 23% (vs. 34% White) |
| Black patients — metastatic lung cancer systemic therapy receipt | 26% (vs. 39% White) |
| Black patients — metastatic prostate cancer systemic therapy receipt | 56% (vs. 77% White) |
| American Indians/Alaska Natives | Highest cancer mortality rates among all racial/ethnic groups (NCI) |
| American Indians/Alaska Natives | Higher death rates from kidney cancer than any other racial/ethnic group |
| Black/African American people | Higher death rates than all other racial/ethnic groups for many cancer types |
| Low-income subsidy status | Explains 20%–45% of racial disparities in metastatic cancer treatment receipt |
Source: NCI Cancer Disparities (cancer.gov/about-cancer/understanding/disparities); CDC, How Racism Leads to Cancer Health Disparities (cdc.gov); Lin JK et al. J Clin Oncol. 2025;43(30):3254–3265. doi:10.1200/JCO-24-02440 (SEER-Medicare data 2016–2020); PMC study on Racial/Ethnic Differences in Cancer Diagnosed after Metastasis (SEER data 2006–2015).
The racial disparities in metastatic cancer diagnosis, treatment, and survival across the United States represent one of the most urgent and under-addressed crises in oncology today. The gap between non-Hispanic Black men — who face a Stage IV cancer diagnosis rate of approximately 337 per 100,000 — and non-Hispanic Asian/Pacific Islander women, at just 117 per 100,000, is a nearly threefold difference that cannot be explained by biology alone. Research drawing on SEER-Medicare linked data from 2016–2020 found stark treatment disparities among patients already diagnosed with metastatic cancer: for metastatic colorectal cancer, only 23% of Black patients received any systemic therapy within two months of diagnosis, compared to 34% of White patients. For metastatic prostate cancer, 56% of Black patients received systemic therapy versus 77% of White patients — a gap that, crucially, disappeared in studies that restricted analysis to patients who did receive treatment, suggesting the disparity is not in how cancer responds to therapy but in who receives it in the first place. This finding points directly to structural barriers — and data confirms that low-income subsidy status alone accounts for 20% to 45% of the racial disparity in metastatic cancer treatment receipt. According to NCI, American Indians and Alaska Natives carry the highest overall cancer mortality rate among all racial/ethnic groups in the US and face uniquely high rates of kidney cancer death — disparities driven in part by geographic isolation from screening centers and systemic underfunding of Indigenous health services.
Metastatic Cancer Age and Gender Trends in the US 2026
| Metric | Data |
|---|---|
| % of all cancer diagnoses in people aged 65+ | 60% |
| % of all cancer diagnoses in people aged 50–64 | 28% |
| % of all cancer diagnoses in people under age 50 | 12% |
| New male cancer diagnoses, 2026 | 1,094,070 |
| New female cancer diagnoses, 2026 | 1,020,780 |
| Estimated new male cancer deaths, 2026 | 327,290 |
| Estimated new female cancer deaths, 2026 | 298,000 |
| Top male cancer deaths — digestive system, 2026 | 102,000 |
| Top male cancer deaths — respiratory, 2026 | 67,260 |
| Top female cancer deaths — digestive system, 2026 | 76,700 |
| Top female cancer deaths — respiratory (lung), 2026 | 63,290 |
| Breast cancer deaths in women, 2026 | 42,140 |
| Prostate cancer deaths in men, 2026 | 36,320 |
| Cancer deaths averted in men (1991–2023) | 3.2 million |
| Cancer deaths averted in women (1992–2023) | 1.5 million |
Source: Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. doi:10.3322/caac.70043. Data from NCI SEER and CDC National Center for Health Statistics.
The age and gender breakdown of cancer in 2026 reveals important truths about who bears the heaviest metastatic burden. With 60% of all cancer diagnoses occurring in Americans aged 65 and older, the collision of an aging US population with late-stage cancer risk is a growing policy and healthcare infrastructure challenge. Yet the data also surfaces a troubling trend: younger adults are not escaping cancer’s reach. A full 12% of all new cancer diagnoses in 2026 will be in Americans under 50, and 28% in the 50–64 age bracket — groups where metastatic diagnoses can mean decades of lost life. On the gender side, men face slightly higher absolute cancer mortality — 327,290 projected deaths vs. 298,000 for women in 2026 — with digestive system cancers claiming the most lives in both sexes. The public health legacy of smoking is written directly into these numbers: 182,830 cancer deaths in 2026 are attributable to direct or secondhand smoke exposure. The gender imbalance in deaths averted since 1991 — 3.2 million for men versus 1.5 million for women — partly reflects that men started from a higher mortality peak and declined faster, driven by more dramatic smoking cessation and the impact of PSA screening-era prostate cancer treatment advances, though questions remain about how much of that is overdiagnosis versus genuine survival improvement.
Metastatic Cancer Progress and Treatment Advances in the US 2026
| Metric | Data / Fact |
|---|---|
| Overall distant-stage survival improvement (mid-1990s to 2015–2021) | 17% → 35% |
| Metastatic lung cancer survival improvement | 2% → 10% |
| Metastatic melanoma survival improvement | 16% → 35% |
| Myeloma survival improvement | 32% → 62% |
| Liver cancer survival improvement | 7% → 22% |
| Pancreatic cancer (all stages) survival improvement | 4% → 13% |
| FDA new anticancer drug approvals (July 2024–June 2025) | 20 new anticancer therapeutics |
| Additional FDA-approved new uses for existing cancer drugs (same period) | 8 new uses approved |
| New early detection screening tests approved (same period) | 2, including first liquid biopsy test |
| % of overall survival improvement at 5-year attributed to treatment advances | ~75% (per ACS analysis) |
| % attributed to earlier diagnosis | ~25% |
| Melanoma mortality annual decline 2013–2017 | ~6% per year |
| Melanoma mortality annual decline 2017–2023 | 1.2% per year |
| Ovarian cancer diagnosed at distant stage (2018–2022) | 49%, down from 57% a decade earlier |
Source: Siegel RL et al. CA Cancer J Clin. 2026. doi:10.3322/caac.70043; American Association for Cancer Research (AACR) Cancer Progress Report 2025 (cancerprogressreport.aacr.org); NCI SEER Program.
The treatment-driven transformation of metastatic cancer outcomes in the US is, by 2026, one of oncology’s most compelling chapters. A key finding from the American Cancer Society’s 2026 Cancer Statistics report is that roughly three-quarters of the overall improvement in cancer survival over recent decades can be attributed to treatment advances — not simply catching cancer earlier. This is particularly evident in the metastatic melanoma story: two decades of stable, dismal survival rates gave way to a nearly 6% annual decline in melanoma mortality from 2013 to 2017 following the introduction of checkpoint inhibitor immunotherapies, representing one of the sharpest treatment-driven survival inflections ever recorded for a major cancer type. The FDA approving 20 new anticancer therapeutics in just one year (July 2024 to June 2025), along with 8 new uses for existing drugs and 2 new screening tests including the first liquid biopsy test for early cancer detection, confirms that the pipeline of innovation remains active. Yet the data also contains a warning. Progress is not uniform — distant-stage pancreatic cancer still sits at 3% five-year survival, and patients with triple-negative metastatic breast cancer continue to face far worse outcomes than those with hormone receptor-positive disease. The liquid biopsy and other early-detection technologies now entering clinical use may offer the next major leap: shifting more patients out of the metastatic category at first diagnosis, which the data strongly suggests is the single most effective way to improve long-term outcomes.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.